Pediatric sarcomas, including osteosarcoma, Ewing sarcoma, and soft tissue sarcomas- are aggressive cancers that require intensive, multimodal treatment. Our integrative oncology program is designed to work alongside standard therapies such as chemotherapy, surgery, and radiation to optimize outcomes, reduce treatment-related toxicity, and support long-term survivorship.

Currently we are implementing the use of Viscum album, alongside tyrosine kinase inhibitors, tumor treating field technology and targeted natural products in the management of relapsed / refractory pediatric sarcomas.